| 000 | 01594 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513053225.0 | ||
| 264 | 0 | _c19941220 | |
| 008 | 199412s 0 0 eng d | ||
| 022 | _a0148-396X | ||
| 024 | 7 |
_a10.1227/00006123-199408000-00003 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRitter, A M | |
| 245 | 0 | 0 |
_aPrognostic significance of bromodeoxyuridine labeling in primary and recurrent glioblastoma multiforme. _h[electronic resource] |
| 260 |
_bNeurosurgery _cAug 1994 |
||
| 300 |
_a192-8; discussion 198 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBrain _xpathology |
| 650 | 0 | 4 |
_aBrain Neoplasms _xmortality |
| 650 | 0 | 4 | _aBromodeoxyuridine |
| 650 | 0 | 4 |
_aCell Division _xphysiology |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGlioblastoma _xmortality |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMitotic Index |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xmortality |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRadiotherapy, Adjuvant |
| 650 | 0 | 4 | _aReoperation |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aSawaya, R | |
| 700 | 1 | _aHess, K R | |
| 700 | 1 | _aLevin, V A | |
| 700 | 1 | _aBruner, J M | |
| 773 | 0 |
_tNeurosurgery _gvol. 35 _gno. 2 _gp. 192-8; discussion 198 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1227/00006123-199408000-00003 _zAvailable from publisher's website |
| 999 |
_c7969156 _d7969156 |
||